PTPI

NASDAQ

Petros Pharmaceuticals Inc.

SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations

News25/Ratings0

Petros Pharmaceuticals, Inc. engages in identifying, acquiring, developing, and commercializing therapeutics for men's health issues in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company develops H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. It also offers prescription medication, such as Stendra for the treatment of male erectile dysfunction; and vacuum erection devices. Petros Pharmaceuticals, Inc. is based in New York, New York.

News · 26 weeks11+100%

2025-10-262026-04-19

Mix390d

Other2(67%)
SEC Filings1(33%)

Latest news

25 items

8dSEC
SEC Form 10-K filed by Petros Pharmaceuticals Inc.
10-K - Petros Pharmaceuticals, Inc. (0001815903) (Filer)
23dSEC
SEC Form NT 10-K filed by Petros Pharmaceuticals Inc.
NT 10-K - Petros Pharmaceuticals, Inc. (0001815903) (Filer)
65dSEC
Amendment: SEC Form SCHEDULE 13G/A filed by Petros Pharmaceuticals Inc.
SCHEDULE 13G/A - Petros Pharmaceuticals, Inc. (0001815903) (Subject)
107dINSIDER
Officer Boctor Fady was granted 500,000 shares, increasing direct ownership by 2,502% to 519,986 units (SEC Form 4)
4 - Petros Pharmaceuticals, Inc. (0001815903) (Issuer)
111dINSIDER
Director Silverman Joshua was granted 4,375,000 shares, increasing direct ownership by 10,816% to 4,415,450 units (SEC Form 4)
4 - Petros Pharmaceuticals, Inc. (0001815903) (Issuer)
111dINSIDER
Director Walker Wayne Remell was granted 500,000 shares, increasing direct ownership by 7,895% to 506,333 units (SEC Form 4)
4 - Petros Pharmaceuticals, Inc. (0001815903) (Issuer)
111dSEC
Petros Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update
8-K - Petros Pharmaceuticals, Inc. (0001815903) (Filer)
111dINSIDER
Director Bernstein Bruce was granted 1,875,000 shares, increasing direct ownership by 15,202% to 1,887,334 units (SEC Form 4)
4 - Petros Pharmaceuticals, Inc. (0001815903) (Issuer)
154dSEC
SEC Form 25-NSE filed by Petros Pharmaceuticals Inc.
25-NSE - Petros Pharmaceuticals, Inc. (0001815903) (Subject)
161dSEC
SEC Form 10-Q filed by Petros Pharmaceuticals Inc.
10-Q - Petros Pharmaceuticals, Inc. (0001815903) (Filer)
167dSEC
Petros Pharmaceuticals Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
8-K - Petros Pharmaceuticals, Inc. (0001815903) (Filer)
230dSEC
Petros Pharmaceuticals Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits
8-K - Petros Pharmaceuticals, Inc. (0001815903) (Filer)
251dSEC
Amendment: SEC Form SCHEDULE 13G/A filed by Petros Pharmaceuticals Inc.
SCHEDULE 13G/A - Petros Pharmaceuticals, Inc. (0001815903) (Subject)
252dSEC
SEC Form 10-Q filed by Petros Pharmaceuticals Inc.
10-Q - Petros Pharmaceuticals, Inc. (0001815903) (Filer)
302dNEWS
Petros Pharmaceuticals Announces Deconsolidation of Metuchen Pharmaceuticals Subsidiary, Strengthening its Balance Sheet and Improving the Company's Equity Position
NEW YORK, NY / ACCESS Newswire / June 25, 2025 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) ("Petros" or the "Company"), a company focused on expanding consumer access to medication through over the counter ("OTC") drug development programs, today announces the strategic deconsolidation of its wholly owned subsidiary, Metuchen Pharmaceuticals LLC ("Metuchen"), including its wholly owned subsidiaries, Timm Medical Technologies, Inc. and Pos-T-Vac, LLC, from its consolidated balance sheet, effective beginning in its Quarterly Report on Form 10-Q for the quarter ending June 30, 2025. This move is expected to significantly improve Petros' financial position, increasing stockholders' equity and m
307dSEC
Petros Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
8-K - Petros Pharmaceuticals, Inc. (0001815903) (Filer)
337dNEWS
Petros Pharmaceuticals Announces Transition from NASDAQ to OTC Markets
The Company Intends to Appeal the Delisting Determination NEW YORK, NY / ACCESS Newswire / May 21, 2025 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) ("Petros" or the "Company"), a company focused on expanding consumer access to medication through over the counter ("OTC") drug development programs, today announces that it has received a staff determination letter from the Nasdaq Stock Market, LLC ("Nasdaq"), informing the Company that Nasdaq determined to suspend trading and delist the Company's common stock from Nasdaq. At the open of trading on Thursday, May 22, 2025, Petros' securities will be suspended on Nasdaq and are expected to begin trading on the OTC Markets under the ticker "PTPI".
337dSEC
Petros Pharmaceuticals Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
8-K - Petros Pharmaceuticals, Inc. (0001815903) (Filer)
338dNEWS
Petros Pharmaceuticals Partners with Innolitics, a Leading Software-as-a-Medical-Device Developer
With more than $10m in cash, and a significantly reduced burn rate, the Company is positioned to fully fund the development of its technology platform. NEW YORK, NY / ACCESS Newswire / May 20, 2025 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) ("Petros" or the "Company"), a company focused on expanding consumer access to medication through over the counter ("OTC") drug development programs, today announces its partnership with Innolitics, a leading developer in the Software-as-a-Medical Device space. The collaboration is intended to integrate many of the Company's emerging capabilities in the ongoing development of its first-in-industry SaaS platform designed to complement its proprietary web
343dSEC
SEC Form 10-Q filed by Petros Pharmaceuticals Inc.
10-Q - Petros Pharmaceuticals, Inc. (0001815903) (Filer)
343dSEC
Amendment: SEC Form SCHEDULE 13G/A filed by Petros Pharmaceuticals Inc.
SCHEDULE 13G/A - Petros Pharmaceuticals, Inc. (0001815903) (Subject)
352dNEWS
Petros Pharmaceuticals Strengthens Partnership with Market Leading Big Data Provider Implementing Key Enhancements to its AI Platform
Company continues to innovate and develop its SaaS-based platform to facilitate Rx-to-OTC switch in line with recent President Trump Executive Order NEW YORK, NY / ACCESS Newswire / May 6, 2025 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) ("Petros" or the "Company"), a company focused on expanding consumer access to medication through over the counter ("OTC") drug development programs, today announces it has implemented multiple enhancements to its developing AI platform, which is expected to improve processing and fraud detection and provide a better overall experience. The AI Platform is expected to be a key component of the Company's recently announced SaaS-based technology, integrating P
356dSEC
Petros Pharmaceuticals Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
8-K - Petros Pharmaceuticals, Inc. (0001815903) (Filer)
357dNEWS
Petros Pharmaceuticals Developing First-in-Industry SaaS Platform Utilizing AI and Electronic Health Records Intended to Facilitate Rx-OTC Switches
Licensable platform intended to facilitate industry compliance with President Trump's recent Executive Order to expand access to medicines through OTC approvals under his Make America Healthy Again (MAHA) initiative NEW YORK, NY / ACCESS Newswire / May 1, 2025 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) ("Petros" or the "Company"), a company focused on expanding consumer access to medication through over the counter ("OTC") drug development programs, today announces a concerted effort toward evolving into a smart healthcare technology company through the development of a SaaS platform designed to complement its proprietary web application (also known as a Software as a Medical Device, or Sa
359dNEWS
Petros Proprietary Technology Platform Aligns with April 15, 2025 President Trump Executive Order Advancing Rx-to-OTC Reclassification Reforms
Company's AI and Big Data technology positioned to drive strong industry collaborationCompany also announces certain corporate actions NEW YORK, NY / ACCESS Newswire / April 29, 2025 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) ("Petros" or the "Company"), a company focused on expanding consumer access to medication through over the counter ("OTC") drug development programs, today highlights President Trump's April 15, 2025 Executive Order, titled, "Lowering Drug Prices By Once Again Putting Americans First" (the "Executive Order"), as a demonstration that the Company's recent strategic shift is well timed to the current regulatory climate, where Petros believes it has already made significa